SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

06 Feb 2026 Evaluate
The revenue zoomed 19.53% to Rs. 2331.02 millions for the quarter ended December 2025 as compared to Rs. 1950.19 millions during the corresponding quarter last year.The Company's Net profit for the December 2025 quarter have declined marginally to Rs. 149.54  millions as against Rs. 152.27 millions reported during the corresponding quarter ended.Operating Profit saw a handsome growth to 288.99 millions from 283.69 millions in the quarter ended December 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 2331.02 1950.19 19.53 6655.90 5571.73 19.46 7598.78 6309.56 20.43
Other Income 45.22 37.31 21.20 134.06 127.05 5.52 176.46 134.68 31.02
PBIDT 288.99 283.69 1.87 928.63 812.72 14.26 1117.61 915.70 22.05
Interest 12.77 14.60 -12.53 33.50 30.55 9.66 43.82 11.03 297.28
PBDT 276.22 269.09 2.65 895.13 782.17 14.44 1073.79 904.67 18.69
Depreciation 76.99 69.39 10.95 227.44 196.50 15.75 279.85 134.44 108.16
PBT 199.23 199.70 -0.24 667.69 585.67 14.00 793.94 770.23 3.08
TAX 49.69 47.43 4.76 163.50 142.03 15.12 187.45 188.79 -0.71
Deferred Tax 5.09 8.20 -37.93 4.61 5.36 -13.99 4.72 15.35 -69.25
PAT 149.54 152.27 -1.79 504.19 443.64 13.65 606.49 581.44 4.31
Equity 105.39 104.50 0.85 105.39 104.50 0.85 104.80 103.99 0.78
PBIDTM(%) 12.40 14.55 -14.77 13.95 14.59 -4.35 14.71 14.51 1.34

Windlas Biotech Share Price

856.85 -6.35 (-0.74%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×